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Heparin-induced thrombocytopenia (HIT) is an immune-mediated thrombocytopenia resulting from prior heparin
exposure. It can be associated with limb- or life-threatening thrombotic events. Patients undergoing any vascular
procedures including endovascular procedures that require heparin administration are at risk. There is very little reported
in the literature with regards to thrombosis associated with HIT after endovascular aortic aneurysm repair. All reported
cases of HIT thrombosis presented as acute arterial lower limb ischemia or deep vein thrombosis. In this report, we
present a case of HIT complicated by stent graft thrombosis and bowel ischemia. (J Vasc Surg 2015;61:234-6.)Heparin is commonly used as an anticoagulant in the
prevention and treatment of thromboembolism during
cardiac and vascular surgery procedures. Despite the clinical
advantage of heparin, some adverse effects with bleeding
and thrombosis may occur. Heparin-induced thrombocyto-
penia (HIT) is a known complication of heparin therapy. It
is deﬁned as a sudden fall in the platelet count and usually
appears a few days after the start of heparin.1 It may manifest
itself as only a slight decrease in platelet count (HIT-I), or it
may be complicated by thrombotic events (HIT-II). For
patients undergoing vascular procedures, in particular endo-
vascular interventions, the body of literature for HIT is
scarce. Only a few case reports2-4 have been published,
and the presentation and incidence are still unknown.
Consent was obtained from the patient to publish these
images and clinical history.
CASE REPORT
A 70-year-old man with a medical history of hypertension,
hyperlipidemia, coronary artery disease, and prostate carcinoma
treated with radio and hormonal therapy underwent elective endo-
vascular repair of an infrarenal abdominal aortic aneurysm. He was
treated with an Endurant, (Medtronic, Santa Rosa, Calif) aorto-
uni-iliac graft, amplatzer occluder of the left common iliac artery,
and a right-to-left femoral-femoral bypass with Dacron graft. The
decision to occlude the left common iliac artery and use an aorto-
uni-iliac conﬁguration was made intraoperatively due to the highthe Division of Vascular Surgery, McGill University, McGill Univer-
y Heath Centre, Royal Victoria Hospital.
or conﬂict of interest: none.
rint requests: Oren K. Steinmetz, MD, McGill University, McGill
niversity Heath Centre, Royal Victoria Hospital, Division of Vascular
rgery, Montreal, Quebec H3A 1A1 Canada (e-mail: oren.steinmetz@
uhc.mcgill.ca).
editors and reviewers of this article have no relevant ﬁnancial relationships
disclose per the JVS policy that requires reviewers to decline review of any
anuscript for which they may have a conﬂict of interest.
-5214
yright  2015 by the Society for Vascular Surgery.
://dx.doi.org/10.1016/j.jvs.2013.08.086degree of tortuosity of the left iliac artery. At the time of the proce-
dure, 5000 IU of unfractionated heparin (UFH) was given intra-
venously. He was discharged on postoperative day 1 after an
uneventful postoperative course on aspirin 80 mg daily. Twelve
days later, the patient presented to the emergency department
with a 1-day history of bloody diarrhea and general malaise. He
had no abdominal pain or other symptoms. His abdominal exam
was unremarkable; the pulse in the femoral-femoral bypass graft
was faint, and distal pedal pulses were not palpable. Platelet count
was only 18,000. Noninvasive vascular studies were performed
upon readmission. Duplex ultrasound revealed a patent right-to-
left femoral-femoral bypass with thrombus visualized throughout
the graft. Ankle-brachial indexes were measured and were 0.48
and 0.45 for the right and left side, respectively. Computerized
tomography (CT) angiogram of the abdomen and pelvis revealed
nonocclusive thrombosis of the aortic graft, the superior mesen-
teric artery (SMA), as well as the femoral-femoral graft (Fig).
There was no technical abnormality such as graft kinking or
stenosis demonstrated on the scan. There was no endoleak, the
inferior mesenteric artery was thrombosed, and the internal iliac
arteries were patent. The CT scan also showed some edema and
thickening of the large bowel wall but no evidence of transmural
bowel ischemia. Based on the patient’s clinical presentation, CT
ﬁndings, and drop in platelet count, the diagnosis was subclinical
bowel ischemia secondary to HIT thrombosis of the aortic stent
graft and the SMA. The patient was treated nonoperatively with
intravenous anticoagulation using argatropan. Intravenous antibi-
otics (metronidazole and tazocin) were started at presentation
and administered for 24 hours. The patient was examined daily
and platelet count followed. The count increased gradually over
time (50,000 at 5 days and 80,000 at 10 days after presentation).
The diagnosis was conﬁrmed by HIT immunoassay (heparin
platelet factor 4), and the bloody diarrhea subsided 10 days after
presentation. Two weeks after initiating anticoagulation therapy
with the use of argatroban, warfarin was started when the patient’s
platelet count reached 100,000. Argatropan was stopped after
3 days of combined anticoagulation therapy; the patient was dis-
charged without any symptoms and normal bowel movements.
Three months later, the patient remained asymptomatic and
Fig. Representative computed tomography (CT) angiogram images at presentation (A-C) and at 3-month follow-up
(D-F) demonstrating signiﬁcant recanalization of the endograft (A vs D) and the right-to-left femoral-femoral graft
(C vs F). Note residual thrombus in the superior mesenteric artery (SMA; arrow) in the follow-up despite signiﬁcant
recanalization of the endograft (B vs E).
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the endograft and femoral-femoral graft and residual thrombus
in the SMA origin (Fig).
DISCUSSION
HIT is a known complication of heparin therapy usually
occurring within the ﬁrst 10 days after heparin treatment has
started.1 Type one (HIT-I), the most common variant, is
typically characterized by a fall in platelet count within the
ﬁrst 2 days after initiation of heparin therapy. This will usually
correct itself with the discontinuation of heparin therapy.5
Thrombocytopenia in this subtype is due to a nonimmune
mechanism secondary to a direct effect of heparin on platelet
activation.5 Type two (HIT-II) is less common and more
aggressive than type one and is also known as heparin-
associated thrombocytopenia and thrombosis. It is an
immune-mediated disorder associated with the formation
of antibodies against the heparin-platelet factor 4 complex.
The overall incidence of HIT-II is 2.6%.6 The inci-
dence is related to the duration of heparin exposure:
0.2% to 5.0% in patients exposed to heparin for more
than 4 days6,7; and 0.2% for those treated with UFH for
less than 4 days.8 HIT-II has a mortality rate of approxi-
mately 20% to 30% and is complicated by limb amputationin 10% to 20% of unrecognized and untreated patients.9
The use of UFH rather than low-molecular-weight
heparin, surgical patients, and female gender are all addi-
tional but less important risk factors for HIT.7,10
HIT is not uncommon with vascular surgery, although
the exact incidence is not clear. An obvious variation is seen
in the literature in the incidence of HIT as conﬁrmed by
HIT assay. It has been shown to be as low as 1.9% in
some reports and as high as 21% in others.11,12 Diagnosing
HIT based on decreased platelet count is difﬁcult in
patients postinsertion of a vascular graft, especially post-
aneurysm repair, as the postoperative thrombocytopenia
could be due to platelet adherence to the graft material.3
To date, HIT secondary to endovascular aneurysm repair
is uncommon with unknown incidence.
Five cases of thrombosis-associated HIT-II have been
reported in three case reports.2-4 All of these HIT-II cases
presented with either acute lower limb ischemia or lower
limb deep vein thrombosis; endograft thrombosis and
mesenteric arterial thrombosis with ischemia have not
been previously reported in the literature.
The primary ﬁnding for diagnosis of HIT is a fall in the
platelet count of more than 50% that occurs within 2 weeks
after using or starting heparin therapy. Different laboratory
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platelet 14C serotonin release assay,14 and heparin-
induced platelet aggregation,15 can all be used for conﬁr-
mation of the diagnosis. Clinical features of HIT can be
either venous thrombosis and/or embolism, including
deep venous thrombosis and pulmonary embolism, or arte-
rial thrombosis involving aorta and major limb arteries,
resulting in limb ischemia.16 Unusual thromboembolic
events and lack of response to heparin with a history of
heparin exposure should raise suspicion of HIT; repeat
platelet counts should be done along with other serologic
tests. After endovascular procedures, HIT may also rarely
manifest as thrombotic complication at the site of
intervention.16,17
In this case, we treated the patient primarily with anti-
coagulation because there was no immediate limb threat
and bowel ischemia was incomplete. We did not consider
more aggressive intervention such as surgical or endovascu-
lar revision or thrombectomy since both would have
carried the potential of graft dislodgment and distal embo-
lization. Intra-arterial thrombolysis was contraindicated
due to profound thrombocytopenia. Treatment of a patient
with HIT starts with immediate cessation of any sources of
heparin and replacement with an anticoagulant therapy
that does not cross-react with HIT antibodies.18,19 Alter-
native anticoagulants include danaparoid, lepirudin, fonda-
parinux, and argatroban.18,19 Warfarin should not be
started for HIT patients until the thrombocytopenia
resolves and patients have been stably anticoagulated with
one of the above anticoagulants. Low-molecular-weight
heparin should not be substituted for UFH after HIT
develops because of frequent cross-reactivity with HIT
antibodies.
CONCLUSIONS
HIT is a rare but potentially limb- and life-threatening
adverse reaction seen in patients exposed to heparin.
Patients undergoing vascular and endovascular procedures
in which large doses of heparin are used are at risk. A high
index of suspicion is required in order to diagnose it and
initiate proper therapy to prevent serious thrombotic
complications.
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